Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of the fiscal period ended Wednesday, December 31, 2025.
Reported annual fiscal-period values; no daily interpolation.
EV/EBIT RATIO
N/A
EV/EBIT RATIO AVG TTM
-15.91x
EV/EBIT RATIO AVG 3Y
N/A
EV/EBIT RATIO AVG 5Y
N/A
EV/EBIT RATIO AVG 10Y
N/A
EV/EBIT RATIO AVG 15Y
N/A
EV/EBIT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Shoulder Innovations, Inc.
Market Cap
$468.68M
EV/EBIT Ratio
N/A
TTM Avg
-15.91x
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.64B
EV/EBIT Ratio
44.64x
TTM Avg
49.71x
3Y Avg
66.02x
5Y Avg
66.02x
Market Cap
$2.76B
EV/EBIT Ratio
23.12x
TTM Avg
19.51x
3Y Avg
19.51x
5Y Avg
21.07x
Market Cap
$7.06B
EV/EBIT Ratio
264.15x
TTM Avg
120.54x
3Y Avg
156.09x
5Y Avg
156.09x
Market Cap
$7.81B
EV/EBIT Ratio
523.77x
TTM Avg
425.19x
3Y Avg
149.58x
5Y Avg
149.58x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Shoulder Innovations, Inc. (SI) | $468.68M | N/A | -15.91x | N/A | N/A |
| NRC Health (NRC)vs › | $440.37M | 35.14x | 19.14x | 18.11x | 19.57x |
| 23andMe Holding Co. (ME)vs › | $15.31M | N/A | -0.28x | -1.89x | -7.82x |
| Teladoc Health, Inc. (TDOC)vs › | $1.26B | N/A | -3.74x | -5.94x | -19.44x |
| TransMedics Group, Inc. (TMDX)vs › | $2.64B | 44.64x | 49.71x | 66.02x | 66.02x |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.76B | 23.12x | 19.51x | 19.51x | 21.07x |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.06B | 264.15x | 120.54x | 156.09x | 156.09x |
| Oscar Health, Inc. (OSCR)vs › | $7.81B | 523.77x | 425.19x | 149.58x | 149.58x |
| Tempus AI, Inc. (TEM)vs › | $8.18B | N/A | -25.82x | -27.80x | -28.85x |
| Insulet Corp. (PODD)vs › | $9.23B | 24.01x | 40.89x | 69.08x | 178.25x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/EBIT RATIO |
|---|---|
| 2025-12-31 | -10.77x |
| 2024-12-31 | -21.05x |
| 2023-12-31 | -28.36x |
